Showing all 3 results
Methylprednisolone Tablet
FreeProduct Composition & Available Strengths
We supply Methylprednisolone in a comprehensive, internationally standardized range of strengths to facilitate both low-dose chronic maintenance and the high-dose taper packs mandatory in clinical steroid therapy.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Target Methylprednisolone USP / BP / IP 4 mg Oral Solid Uncoated Tablet (Cross-scored for micro-titration) Baseline Dose / Tapering: For rheumatoid arthritis maintenance and step-down dose regimens. Methylprednisolone USP / BP / IP 8 mg Oral Solid Uncoated Tablet (Cross-scored for micro-titration) Intermediate Management: For moderate asthma exacerbations and chronic dermatological conditions. Methylprednisolone USP / BP / IP 16 mg Oral Solid Uncoated Tablet (Cross-scored for flexible division) High-Potency Control: For acute autoimmune flares, immunosuppression in organ transplants, and oncology support. Metronidazole Tablet
FreeProduct Composition & Available Strengths
We supply Metronidazole in standard, internationally recognized strengths optimized for adult and pediatric treatment regimens.
Active Ingredient Available Strengths Common Dosage Matrix Primary Clinical Target Metronidazole BP / IP / USP 200 mg Film-Coated / Uncoated Oral Tablet Pediatric & Low-Dose Titration: For delicate adjustments in mild amoebic dysentery or combination protocols. Metronidazole BP / IP / USP 400 mg Film-Coated / Uncoated Oral Tablet Standard Generic Backbone: Standard twice or thrice-daily dosing for dental abscesses and Giardiasis. Metronidazole BP / IP / USP 500 mg High-Potency Oral Tablet Institutional Target: High-volume strength preferred for anaerobic surgical prophylaxis and severe trichomoniasis. Olanzepine Tablet
FreeProduct Composition & Available Strengths
We supply Olanzapine in standard, exact strengths to facilitate initial titration phases and safe daily maintenance therapy.
Active Ingredient Available Strengths Primary Clinical Target Olanzapine IP / BP / USP 2.5 mg Introductory Titration: For low-dose introductory cycles, elderly adjustment, or sensitive patient profiles. Olanzapine IP / BP / USP 5 mg Standard Maintenance: The baseline daily dosage for long-term schizophrenic and bipolar maintenance. Olanzapine IP / BP / USP 10 mg Acute Crisis Control: High-potency therapeutic dosing to stabilize acute manic or severe psychotic episodes.
